ArticleTargeted oncology2024

Real-World Primary Resistance to First-Line Immune-Based Combinations in Patients with Advanced Renal Cell Carcinoma (ARON-1).

Daniele Santini et al.PubMed ↗Publisher ↗

No numbers read from the abstract.